MDM2 protein expression is a negative prognostic marker in breast carcinoma
Open Access
- 2 September 2005
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 19 (1), 69-74
- https://doi.org/10.1038/modpathol.3800484
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Prognostic Relevance of Gene Amplifications and Coamplifications in Breast CancerCancer Research, 2004
- Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue MicroarraysThe American Journal of Pathology, 2002
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical EndpointsThe American Journal of Pathology, 2001
- MDM2 Enhances the Function of Estrogen Receptor α in Human Breast Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Functions of the MDM2 oncoproteinCellular and Molecular Life Sciences, 1999
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein statusBritish Journal of Cancer, 1995
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992